{"transactions":[{"id":1773325,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-09-26T16:30:32.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2137,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, withot uinterest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, withot uinterest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"derivative":{"exercise_price":93.61,"expiration_date":"2033-06-07","underlying":"Class A common stock","underlying_shares":2137},"source":{"system":"sec-edgar","filing":"0000899243-23-019539","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1685986/000089924323019539/doc4.xml","form_type":"4"}},{"id":1773324,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-09-26T16:30:32.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":576,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, withot uinterest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, withot uinterest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"derivative":{"exercise_price":93.61,"expiration_date":"2033-06-07","underlying":"Class A common stock","underlying_shares":576},"source":{"system":"sec-edgar","filing":"0000899243-23-019539","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1685986/000089924323019539/doc4.xml","form_type":"4"}},{"id":1773323,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-09-26T16:30:32.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1405,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, withot uinterest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, withot uinterest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"derivative":{"exercise_price":34.76,"expiration_date":"2032-06-08","underlying":"Class A common stock","underlying_shares":1405},"source":{"system":"sec-edgar","filing":"0000899243-23-019539","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1685986/000089924323019539/doc4.xml","form_type":"4"}},{"id":1773322,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-09-26T16:30:32.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":443,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, withot uinterest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, withot uinterest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"derivative":{"exercise_price":34.76,"expiration_date":"2032-06-08","underlying":"Class A common stock","underlying_shares":443},"source":{"system":"sec-edgar","filing":"0000899243-23-019539","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1685986/000089924323019539/doc4.xml","form_type":"4"}},{"id":1773321,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-09-26T16:30:32.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":780,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, withot uinterest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, withot uinterest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"derivative":{"exercise_price":146.01,"expiration_date":"2031-06-10","underlying":"Class A common stock","underlying_shares":780},"source":{"system":"sec-edgar","filing":"0000899243-23-019539","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1685986/000089924323019539/doc4.xml","form_type":"4"}},{"id":1773320,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-09-26T16:30:32.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, withot uinterest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, withot uinterest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"derivative":{"exercise_price":146.01,"expiration_date":"2031-06-10","underlying":"Class A common stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000899243-23-019539","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1685986/000089924323019539/doc4.xml","form_type":"4"}},{"id":1773319,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-09-26T16:30:32.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3334,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, withot uinterest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, withot uinterest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"derivative":{"exercise_price":92.2,"expiration_date":"2031-04-15","underlying":"Class A common stock","underlying_shares":3334},"source":{"system":"sec-edgar","filing":"0000899243-23-019539","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1685986/000089924323019539/doc4.xml","form_type":"4"}},{"id":1773318,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A common stock","published_at":"2023-09-26T16:30:32.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7359,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, withot uinterest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-019539","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685986/000089924323019539/doc4.xml","form_type":"4"}},{"id":1819220,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-08-01T16:41:54.000Z","date":"2023-07-28","kind":"exercise","planned":true,"acquired":false,"shares":319,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options vested on July 15, 2021."}],"balance_after":0,"derivative":{"exercise_price":92.2,"expiration_date":"2031-04-15","underlying":"Class A common stock","underlying_shares":319},"source":{"system":"sec-edgar","filing":"0001209191-23-044004","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1685986/000120919123044004/doc4.xml","form_type":"4"}},{"id":1819219,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-08-01T16:41:54.000Z","date":"2023-07-28","kind":"exercise","planned":true,"acquired":false,"shares":6666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest in three equal yearly installments through April 15, 2024, subject to continued service through each vesting date."}],"balance_after":3334,"derivative":{"exercise_price":92.2,"expiration_date":"2031-04-15","underlying":"Class A common stock","underlying_shares":6666},"source":{"system":"sec-edgar","filing":"0001209191-23-044004","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1685986/000120919123044004/doc4.xml","form_type":"4"}},{"id":1819218,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-08-01T16:41:54.000Z","date":"2023-07-28","kind":"exercise","planned":true,"acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested on July 15, 2021."}],"balance_after":0,"derivative":{"exercise_price":92.2,"expiration_date":"2031-04-15","underlying":"Class A common stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001209191-23-044004","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1685986/000120919123044004/doc4.xml","form_type":"4"}},{"id":1819217,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A common stock","published_at":"2023-08-01T16:41:54.000Z","date":"2023-07-28","kind":"sale","planned":true,"acquired":false,"shares":8235,"price":164.5279,"value":1354887.2565,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $164.25 to $164.69. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":7359,"source":{"system":"sec-edgar","filing":"0001209191-23-044004","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1685986/000120919123044004/doc4.xml","form_type":"4"}},{"id":1819216,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A common stock","published_at":"2023-08-01T16:41:54.000Z","date":"2023-07-28","kind":"exercise","planned":true,"acquired":true,"shares":319,"price":92.2,"value":29411.8,"ownership":{"direct":true},"balance_after":15594,"source":{"system":"sec-edgar","filing":"0001209191-23-044004","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1685986/000120919123044004/doc4.xml","form_type":"4"}},{"id":1819215,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A common stock","published_at":"2023-08-01T16:41:54.000Z","date":"2023-07-28","kind":"exercise","planned":true,"acquired":true,"shares":6666,"price":92.2,"value":614605.2,"ownership":{"direct":true},"balance_after":15275,"source":{"system":"sec-edgar","filing":"0001209191-23-044004","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1685986/000120919123044004/doc4.xml","form_type":"4"}},{"id":1819214,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A common stock","published_at":"2023-08-01T16:41:54.000Z","date":"2023-07-28","kind":"exercise","planned":true,"acquired":true,"shares":1250,"price":92.2,"value":115250.0,"ownership":{"direct":true},"balance_after":8609,"source":{"system":"sec-edgar","filing":"0001209191-23-044004","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685986/000120919123044004/doc4.xml","form_type":"4"}},{"id":1860561,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right-to-buy)","published_at":"2023-06-09T16:32:28.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":2137,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests in 4 equal installments on September 7, 2023, December 7, 2023, March 7, 2024, and June 5, 2024, subject to continued service through each vesting date."}],"balance_after":2137,"derivative":{"exercise_price":93.61,"expiration_date":"2033-06-07","underlying":"Class A common stock","underlying_shares":2137},"source":{"system":"sec-edgar","filing":"0001209191-23-035879","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1685986/000120919123035879/doc4.xml","form_type":"4"}},{"id":1860560,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right-to-buy)","published_at":"2023-06-09T16:32:28.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":576,"price":73.68,"value":42439.68,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This option was issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of future director fees of $42,441."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests in 4 equal installments on September 7, 2023, December 7, 2023, March 7, 2024, and June 5, 2024, subject to continued service through each vesting date."}],"balance_after":576,"derivative":{"exercise_price":93.61,"expiration_date":"2033-06-07","underlying":"Class A common stock","underlying_shares":576},"source":{"system":"sec-edgar","filing":"0001209191-23-035879","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1685986/000120919123035879/doc4.xml","form_type":"4"}},{"id":1860559,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A common stock","published_at":"2023-06-09T16:32:28.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":1682,"price":93.61,"value":157452.02,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares represent Restricted Stock Units (RSUs), which vest on June 5, 2024, subject to continued service through the vesting date."}],"balance_after":7359,"source":{"system":"sec-edgar","filing":"0001209191-23-035879","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1685986/000120919123035879/doc4.xml","form_type":"4"}},{"id":1860558,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A common stock","published_at":"2023-06-09T16:32:28.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":454,"price":93.61,"value":42498.94,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares represent Restricted Stock Units (RSUs), which vest on June 5, 2024, subject to continued service through the vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These RSUs were issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of future director fees of $42,499."}],"balance_after":5677,"source":{"system":"sec-edgar","filing":"0001209191-23-035879","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685986/000120919123035879/doc4.xml","form_type":"4"}},{"id":1956847,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right-to-buy)","published_at":"2023-03-13T17:23:56.000Z","date":"2023-03-10","kind":"exercise","acquired":false,"shares":4215,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest in four equal installments on September 14, 2022, December 8, 2022, March 1, 2023, and June 7, 2023, subject to continued service through each vesting date."}],"balance_after":1405,"derivative":{"exercise_price":34.76,"expiration_date":"2032-06-08","underlying":"Class A common stock","underlying_shares":4215},"source":{"system":"sec-edgar","filing":"0001209191-23-018231","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1685986/000120919123018231/doc4.xml","form_type":"4"}},{"id":1956846,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right-to-buy)","published_at":"2023-03-13T17:23:56.000Z","date":"2023-03-10","kind":"exercise","acquired":false,"shares":1326,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest in four equal installments on September 14, 2022, December 8, 2022, March 1, 2023, and June 7, 2023, subject to continued service through each vesting date."}],"balance_after":443,"derivative":{"exercise_price":34.76,"expiration_date":"2032-06-08","underlying":"Class A common stock","underlying_shares":1326},"source":{"system":"sec-edgar","filing":"0001209191-23-018231","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1685986/000120919123018231/doc4.xml","form_type":"4"}},{"id":1956845,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-03-13T17:23:56.000Z","date":"2023-03-10","kind":"exercise","acquired":false,"shares":199,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vested in two equal installments on March 10, 2022 and June 10, 2022."}],"balance_after":0,"derivative":{"exercise_price":27.32,"expiration_date":"2032-01-03","underlying":"Class A common stock","underlying_shares":199},"source":{"system":"sec-edgar","filing":"0001209191-23-018231","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1685986/000120919123018231/doc4.xml","form_type":"4"}},{"id":1956844,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A common stock","published_at":"2023-03-13T17:23:56.000Z","date":"2023-03-10","kind":"sale","acquired":false,"shares":5740,"price":83.73,"value":480610.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $83.67 to $83.86. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":5223,"source":{"system":"sec-edgar","filing":"0001209191-23-018231","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1685986/000120919123018231/doc4.xml","form_type":"4"}},{"id":1956843,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A common stock","published_at":"2023-03-13T17:23:56.000Z","date":"2023-03-10","kind":"exercise","acquired":true,"shares":4215,"price":34.76,"value":146513.4,"ownership":{"direct":true},"balance_after":10963,"source":{"system":"sec-edgar","filing":"0001209191-23-018231","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1685986/000120919123018231/doc4.xml","form_type":"4"}},{"id":1956842,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A common stock","published_at":"2023-03-13T17:23:56.000Z","date":"2023-03-10","kind":"exercise","acquired":true,"shares":1326,"price":34.76,"value":46091.76,"ownership":{"direct":true},"balance_after":6748,"source":{"system":"sec-edgar","filing":"0001209191-23-018231","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1685986/000120919123018231/doc4.xml","form_type":"4"}},{"id":1956841,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A common stock","published_at":"2023-03-13T17:23:56.000Z","date":"2023-03-10","kind":"exercise","acquired":true,"shares":199,"price":27.32,"value":5436.68,"ownership":{"direct":true},"balance_after":5422,"source":{"system":"sec-edgar","filing":"0001209191-23-018231","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685986/000120919123018231/doc4.xml","form_type":"4"}},{"id":2237783,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right-to-buy)","published_at":"2022-06-09T16:47:25.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":5620,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest in four equal installments on September 14, 2022, December 8, 2022, March 1, 2023, and June 7, 2023, subject to continued service through the vesting date."}],"balance_after":5620,"derivative":{"exercise_price":34.76,"expiration_date":"2032-06-08","underlying":"Class A common stock","underlying_shares":5620},"source":{"system":"sec-edgar","filing":"0001209191-22-035423","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1685986/000120919122035423/doc4.xml","form_type":"4"}},{"id":2237782,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right-to-buy)","published_at":"2022-06-09T16:47:25.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":1769,"price":24.02,"value":42491.38,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These options were issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of director fees of $42,500.00."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest in four equal installments on September 14, 2022, December 8, 2022, March 1, 2023, and June 7, 2023, subject to continued service through the vesting date."}],"balance_after":1769,"derivative":{"exercise_price":34.76,"expiration_date":"2032-06-08","underlying":"Class A common stock","underlying_shares":1769},"source":{"system":"sec-edgar","filing":"0001209191-22-035423","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1685986/000120919122035423/doc4.xml","form_type":"4"}},{"id":2237781,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A common stock","published_at":"2022-06-09T16:47:25.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":3883,"price":34.76,"value":134973.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares represent Restricted Stock Units (RSU), which vest in four equal installments on September 14, 2022, December 8, 2022, March 1, 2023, and June 7, 2023, subject to continued service through the vesting date."}],"balance_after":5223,"source":{"system":"sec-edgar","filing":"0001209191-22-035423","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1685986/000120919122035423/doc4.xml","form_type":"4"}},{"id":2237780,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A common stock","published_at":"2022-06-09T16:47:25.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":1222,"price":34.76,"value":42476.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares represent Restricted Stock Units (RSU), which vest in four equal installments on September 14, 2022, December 8, 2022, March 1, 2023, and June 7, 2023, subject to continued service through the vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These RSUs were issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of director fees of $42,500.00."}],"balance_after":1340,"source":{"system":"sec-edgar","filing":"0001209191-22-035423","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685986/000120919122035423/doc4.xml","form_type":"4"}},{"id":2444026,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-01-05T16:04:26.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":199,"price":16.14,"value":3211.86,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These options were issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of director fees of $3,225."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest in 2 equal installments on March 10, 2022 and June 10, 2022, subject to continued service through each vesting date."}],"balance_after":199,"derivative":{"exercise_price":27.32,"expiration_date":"2032-01-03","underlying":"Class A common stock","underlying_shares":199},"source":{"system":"sec-edgar","filing":"0001209191-22-001627","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1685986/000120919122001627/doc4.xml","form_type":"4"}},{"id":2444025,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A common stock","published_at":"2022-01-05T16:04:26.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":118,"price":27.32,"value":3223.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares represent Restricted Stock Units (RSU), which vest on June 8, 2022, subject to continued service through the vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These RSUs were issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of director fees of $3,225."}],"balance_after":118,"source":{"system":"sec-edgar","filing":"0001209191-22-001627","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685986/000120919122001627/doc4.xml","form_type":"4"}},{"id":2670225,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-14T11:33:43.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":780,"price":83.24,"value":64927.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This option was issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of director fees of $65,000."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in 4 equal installments on September 10, 2021, December 10, 2021, March 10, 2022, and June 10, 2022, subject to continued service through each vesting date."}],"balance_after":780,"derivative":{"exercise_price":146.01,"expiration_date":"2031-06-10","underlying":"Class A common stock","underlying_shares":780},"source":{"system":"sec-edgar","filing":"0001209191-21-040142","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1685986/000120919121040142/doc4.xml","form_type":"4"}},{"id":2670224,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-14T11:33:43.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in 4 equal installments on September 10, 2021, December 10, 2021, March 10, 2022, and June 10, 2022, subject to continued service through each vesting date."}],"balance_after":5000,"derivative":{"exercise_price":146.01,"expiration_date":"2031-06-10","underlying":"Class A common stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-21-040142","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685986/000120919121040142/doc4.xml","form_type":"4"}},{"id":2747156,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-04-16T13:38:28.000Z","date":"2021-04-15","kind":"grant","acquired":true,"shares":319,"price":52.85,"value":16859.15,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This option was issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of future director fees of $16,875"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest on July 15, 2021, subject to continued service through the vesting date."}],"balance_after":319,"derivative":{"exercise_price":92.2,"expiration_date":"2031-04-15","underlying":"Class A common stock","underlying_shares":319},"source":{"system":"sec-edgar","filing":"0001209191-21-026923","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1685986/000120919121026923/doc4.xml","form_type":"4"}},{"id":2747155,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-04-16T13:38:28.000Z","date":"2021-04-15","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in three equal yearly installments through April 15, 2024, subject to continued service through each vesting date."}],"balance_after":10000,"derivative":{"exercise_price":92.2,"expiration_date":"2031-04-15","underlying":"Class A common stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-026923","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1685986/000120919121026923/doc4.xml","form_type":"4"}},{"id":2747154,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-04-16T13:38:28.000Z","date":"2021-04-15","kind":"grant","acquired":true,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest on July 15, 2021, subject to continued service through the vesting date."}],"balance_after":1250,"derivative":{"exercise_price":92.2,"expiration_date":"2031-04-15","underlying":"Class A common stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001209191-21-026923","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685986/000120919121026923/doc4.xml","form_type":"4"}},{"id":3919475,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Regulatory Affairs"}}],"security":"Restricted Stock Units","published_at":"2018-05-24T22:06:15.000Z","date":"2018-05-22","kind":"exercise","acquired":false,"shares":4432,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 10, 2017, the reporting person was granted restricted stock units that vest based on the Company's satisfaction of certain performance criteria. The first performance criterion was met on August 3, 2017, resulting in vesting of 50% of such restricted stock units, and the second performance criterion was met on May 22, 2018, resulting in vesting of 25% of such restricted stock units."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 10, 2017, the reporting person was granted restricted stock units that vest based on the Company's satisfaction of certain performance criteria. The first performance criterion was met on August 3, 2017, resulting in vesting of 50% of such restricted stock units, and the second performance criterion was met on May 22, 2018, resulting in vesting of 25% of such restricted stock units."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4432},"source":{"system":"sec-edgar","filing":"0001209191-18-033112","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118033112/doc4.xml","form_type":"4"}},{"id":3919474,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Regulatory Affairs"}}],"security":"Common Stock","published_at":"2018-05-24T22:06:15.000Z","date":"2018-05-22","kind":"tax_withholding","acquired":false,"shares":1305,"price":89.22,"value":116432.1,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock units granted on March 10, 2017."}],"balance_after":31936,"source":{"system":"sec-edgar","filing":"0001209191-18-033112","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118033112/doc4.xml","form_type":"4"}},{"id":3919473,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Regulatory Affairs"}}],"security":"Common Stock","published_at":"2018-05-24T22:06:15.000Z","date":"2018-05-22","kind":"exercise","acquired":true,"shares":4432,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":33241,"source":{"system":"sec-edgar","filing":"0001209191-18-033112","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118033112/doc4.xml","form_type":"4"}},{"id":3993700,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Regulatory Affairs"}}],"security":"Stock option (right to buy)","published_at":"2018-03-16T22:13:22.000Z","date":"2018-03-15","kind":"exercise","acquired":false,"shares":2031,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":10066,"derivative":{"exercise_price":26.24,"exercise_date":"2014-01-02","expiration_date":"2023-01-02","underlying":"Common Stock","underlying_shares":2031},"source":{"system":"sec-edgar","filing":"0001209191-18-020355","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118020355/doc4.xml","form_type":"4"}},{"id":3993699,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Regulatory Affairs"}}],"security":"Stock option (right to buy)","published_at":"2018-03-16T22:13:22.000Z","date":"2018-03-15","kind":"exercise","acquired":false,"shares":469,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6134,"derivative":{"exercise_price":13.9,"exercise_date":"2016-02-27","expiration_date":"2025-02-27","underlying":"Common Stock","underlying_shares":469},"source":{"system":"sec-edgar","filing":"0001209191-18-020355","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118020355/doc4.xml","form_type":"4"}},{"id":3993698,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Regulatory Affairs"}}],"security":"Common Stock","published_at":"2018-03-16T22:13:22.000Z","date":"2018-03-15","kind":"tax_withholding","acquired":false,"shares":656,"price":81.22,"value":53280.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person delivered already-owned shares of Common Stock in payment of the option exercise price. Such an \"option swap\" enables the exercise and holding of shares of Common Stock by the Reporting Person."}],"balance_after":28809,"source":{"system":"sec-edgar","filing":"0001209191-18-020355","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118020355/doc4.xml","form_type":"4"}},{"id":3993697,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Regulatory Affairs"}}],"security":"Common Stock","published_at":"2018-03-16T22:13:22.000Z","date":"2018-03-15","kind":"exercise","acquired":true,"shares":2031,"price":26.24,"value":53293.44,"ownership":{"direct":true},"balance_after":29465,"source":{"system":"sec-edgar","filing":"0001209191-18-020355","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118020355/doc4.xml","form_type":"4"}},{"id":3993696,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Regulatory Affairs"}}],"security":"Common Stock","published_at":"2018-03-16T22:13:22.000Z","date":"2018-03-15","kind":"tax_withholding","acquired":false,"shares":80,"price":81.22,"value":6497.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person delivered already-owned shares of Common Stock in payment of the option exercise price. Such an \"option swap\" enables the exercise and holding of shares of Common Stock by the Reporting Person."}],"balance_after":27434,"source":{"system":"sec-edgar","filing":"0001209191-18-020355","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118020355/doc4.xml","form_type":"4"}},{"id":3993695,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Regulatory Affairs"}}],"security":"Common Stock","published_at":"2018-03-16T22:13:22.000Z","date":"2018-03-15","kind":"exercise","acquired":true,"shares":469,"price":13.9,"value":6519.1,"ownership":{"direct":true},"balance_after":27514,"source":{"system":"sec-edgar","filing":"0001209191-18-020355","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118020355/doc4.xml","form_type":"4"}},{"id":4009167,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Regulatory Affairs"}}],"security":"Stock option (right to buy)","published_at":"2018-03-07T23:06:15.000Z","date":"2018-03-05","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant."}],"balance_after":70000,"derivative":{"exercise_price":71.45,"expiration_date":"2028-03-05","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001209191-18-017794","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118017794/doc4.xml","form_type":"4"}},{"id":4169522,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Regulatory Affairs & Qual"}}],"security":"Non-Qualified Stock Options (right to buy)","published_at":"2017-11-09T01:13:39.000Z","date":"2017-11-06","kind":"exercise","acquired":false,"shares":10000,"price":14.76,"value":147600.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 12, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":31144,"derivative":{"exercise_price":14.76,"exercise_date":"2016-05-06","expiration_date":"2025-05-06","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-17-059861","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919117059861/doc4.xml","form_type":"4"}},{"id":4169521,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Regulatory Affairs & Qual"}}],"security":"Common Stock","published_at":"2017-11-09T01:13:39.000Z","date":"2017-11-06","kind":"sale","acquired":false,"shares":10000,"price":55,"value":550000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 12, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":27045,"source":{"system":"sec-edgar","filing":"0001209191-17-059861","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919117059861/doc4.xml","form_type":"4"}},{"id":4169520,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Regulatory Affairs & Qual"}}],"security":"Common Stock","published_at":"2017-11-09T01:13:39.000Z","date":"2017-11-06","kind":"exercise","acquired":true,"shares":10000,"price":14.76,"value":147600.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 12, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":37045,"source":{"system":"sec-edgar","filing":"0001209191-17-059861","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919117059861/doc4.xml","form_type":"4"}},{"id":4191427,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Regulatory Affairs & Qual"}}],"security":"Non-Qualified Stock Options (right to buy)","published_at":"2017-10-05T23:24:05.000Z","date":"2017-10-03","kind":"exercise","acquired":false,"shares":11500,"price":14.76,"value":169740.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 12, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":41144,"derivative":{"exercise_price":14.76,"exercise_date":"2016-05-06","expiration_date":"2025-05-06","underlying":"Common Stock","underlying_shares":11500},"source":{"system":"sec-edgar","filing":"0001209191-17-056202","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919117056202/doc4.xml","form_type":"4"}},{"id":4191426,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Regulatory Affairs & Qual"}}],"security":"Common Stock","published_at":"2017-10-05T23:24:05.000Z","date":"2017-10-03","kind":"sale","acquired":false,"shares":11500,"price":50,"value":575000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 12, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":27045,"source":{"system":"sec-edgar","filing":"0001209191-17-056202","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919117056202/doc4.xml","form_type":"4"}},{"id":4191425,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Regulatory Affairs & Qual"}}],"security":"Common Stock","published_at":"2017-10-05T23:24:05.000Z","date":"2017-10-03","kind":"exercise","acquired":true,"shares":11500,"price":14.76,"value":169740.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 12, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":38545,"source":{"system":"sec-edgar","filing":"0001209191-17-056202","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919117056202/doc4.xml","form_type":"4"}},{"id":4241812,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Regulatory Affairs & Qual"}}],"security":"Restricted Stock Units","published_at":"2017-08-07T20:44:27.000Z","date":"2017-08-03","kind":"exercise","acquired":false,"shares":8865,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 3, 2017, the reporting person was granted restricted stock units that vest based on the Company's satisfaction of certain performance criteria. The first performance criterion was met on August 3, 2017, resulting in vesting of 50% of such restricted stock units."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 3, 2017, the reporting person was granted restricted stock units that vest based on the Company's satisfaction of certain performance criteria. The first performance criterion was met on August 3, 2017, resulting in vesting of 50% of such restricted stock units."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8865},"source":{"system":"sec-edgar","filing":"0001209191-17-047903","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919117047903/doc4.xml","form_type":"4"}},{"id":4241811,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Regulatory Affairs & Qual"}}],"security":"Common Stock","published_at":"2017-08-07T20:44:27.000Z","date":"2017-08-03","kind":"tax_withholding","acquired":false,"shares":2882,"price":37.88,"value":109170.16,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock units granted on March 3, 2017."}],"balance_after":27045,"source":{"system":"sec-edgar","filing":"0001209191-17-047903","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919117047903/doc4.xml","form_type":"4"}},{"id":4241810,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Regulatory Affairs & Qual"}}],"security":"Common Stock","published_at":"2017-08-07T20:44:27.000Z","date":"2017-08-03","kind":"exercise","acquired":true,"shares":8865,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":29927,"source":{"system":"sec-edgar","filing":"0001209191-17-047903","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919117047903/doc4.xml","form_type":"4"}},{"id":4253543,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Regulatory Affairs & Qual"}}],"security":"Incentive Stock Option (right to buy)","published_at":"2017-07-22T01:47:09.000Z","date":"2017-07-21","kind":"exercise","acquired":false,"shares":1500,"price":14.76,"value":22140.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 12, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":52644,"derivative":{"exercise_price":14.76,"exercise_date":"2015-05-06","expiration_date":"2025-05-06","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001209191-17-046037","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919117046037/doc4.xml","form_type":"4"}},{"id":4253542,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Regulatory Affairs & Qual"}}],"security":"Non-Qualified Stock Options (right to buy)","published_at":"2017-07-22T01:47:09.000Z","date":"2017-07-21","kind":"exercise","acquired":false,"shares":4388,"price":13.9,"value":60993.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 12, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":5098,"derivative":{"exercise_price":13.9,"exercise_date":"2016-02-27","expiration_date":"2025-02-27","underlying":"Common Stock","underlying_shares":4388},"source":{"system":"sec-edgar","filing":"0001209191-17-046037","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919117046037/doc4.xml","form_type":"4"}},{"id":4253541,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Regulatory Affairs & Qual"}}],"security":"Non-Qualified Stock Options (right to buy)","published_at":"2017-07-22T01:47:09.000Z","date":"2017-07-20","kind":"exercise","acquired":false,"shares":6250,"price":13.71,"value":85687.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 12, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":17708,"derivative":{"exercise_price":13.71,"exercise_date":"2017-02-28","expiration_date":"2026-02-28","underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001209191-17-046037","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919117046037/doc4.xml","form_type":"4"}},{"id":4253540,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Regulatory Affairs & Qual"}}],"security":"Common Stock","published_at":"2017-07-22T01:47:09.000Z","date":"2017-07-21","kind":"sale","acquired":true,"shares":1500,"price":44,"value":66000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 12, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":21062,"source":{"system":"sec-edgar","filing":"0001209191-17-046037","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919117046037/doc4.xml","form_type":"4"}},{"id":4253539,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Regulatory Affairs & Qual"}}],"security":"Common Stock","published_at":"2017-07-22T01:47:09.000Z","date":"2017-07-21","kind":"exercise","acquired":true,"shares":1500,"price":14.76,"value":22140.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 12, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":22562,"source":{"system":"sec-edgar","filing":"0001209191-17-046037","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919117046037/doc4.xml","form_type":"4"}},{"id":4253538,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Regulatory Affairs & Qual"}}],"security":"Common Stock","published_at":"2017-07-22T01:47:09.000Z","date":"2017-07-21","kind":"sale","acquired":false,"shares":4388,"price":44,"value":193072.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 12, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":21062,"source":{"system":"sec-edgar","filing":"0001209191-17-046037","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919117046037/doc4.xml","form_type":"4"}},{"id":4253537,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Regulatory Affairs & Qual"}}],"security":"Common Stock","published_at":"2017-07-22T01:47:09.000Z","date":"2017-07-21","kind":"exercise","acquired":true,"shares":4388,"price":13.9,"value":60993.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 12, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":25450,"source":{"system":"sec-edgar","filing":"0001209191-17-046037","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919117046037/doc4.xml","form_type":"4"}},{"id":4253536,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Regulatory Affairs & Qual"}}],"security":"Common Stock","published_at":"2017-07-22T01:47:09.000Z","date":"2017-07-20","kind":"sale","acquired":false,"shares":6250,"price":42,"value":262500.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 12, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":21062,"source":{"system":"sec-edgar","filing":"0001209191-17-046037","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919117046037/doc4.xml","form_type":"4"}},{"id":4253535,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Regulatory Affairs & Qual"}}],"security":"Common Stock","published_at":"2017-07-22T01:47:09.000Z","date":"2017-07-20","kind":"exercise","acquired":true,"shares":6250,"price":13.71,"value":85687.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 12, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":27312,"source":{"system":"sec-edgar","filing":"0001209191-17-046037","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919117046037/doc4.xml","form_type":"4"}},{"id":4376935,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Regulatory Affairs & Qual"}}],"security":"Common Stock","published_at":"2017-03-21T22:01:55.000Z","date":"2017-03-19","kind":"tax_withholding","acquired":false,"shares":177,"price":30.3,"value":5363.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock granted on 9/19/2016."}],"balance_after":21062,"source":{"system":"sec-edgar","filing":"0001209191-17-022104","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919117022104/doc4.xml","form_type":"4"}},{"id":4387343,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Regulatory Affairs & Qual"}}],"security":"Incentive Stock Option (right to buy)","published_at":"2017-03-15T01:50:21.000Z","date":"2017-03-10","kind":"grant","acquired":true,"shares":4189,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant."}],"balance_after":4189,"derivative":{"exercise_price":32.63,"expiration_date":"2027-03-10","underlying":"Common Stock","underlying_shares":4189},"source":{"system":"sec-edgar","filing":"0001209191-17-020691","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919117020691/doc4.xml","form_type":"4"}},{"id":4387342,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Regulatory Affairs & Qual"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2017-03-15T01:50:21.000Z","date":"2017-03-10","kind":"grant","acquired":true,"shares":20811,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant."}],"balance_after":20811,"derivative":{"exercise_price":32.63,"expiration_date":"2027-03-10","underlying":"Common Stock","underlying_shares":20811},"source":{"system":"sec-edgar","filing":"0001209191-17-020691","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919117020691/doc4.xml","form_type":"4"}},{"id":4561199,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Regulatory Affairs & Qual"}}],"security":"Incentive Stock Option (right to buy)","published_at":"2016-11-10T13:20:18.000Z","date":"2016-11-08","kind":"exercise","acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the option became exercisable on the first anniversary of the date of hire (01/02/2013) and 1/48th of the total granted option becomes exercisable on each monthly anniversary thereafter, such that the option will be fully exercisable on the fourth anniversary of the date of hire."}],"balance_after":12097,"derivative":{"exercise_price":26.24,"expiration_date":"2023-01-02","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001209191-16-149228","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919116149228/doc4.xml","form_type":"4"}},{"id":4561198,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Regulatory Affairs & Qual"}}],"security":"Common Stock","published_at":"2016-11-10T13:20:18.000Z","date":"2016-11-08","kind":"exercise","acquired":true,"shares":1000,"price":26.24,"value":26240.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 15,300 Restricted Stock Award (\"RSA\") that will vest upon the Company exceeding $80 million in total revenue reported in publicly released GAAP financials, in any fiscal quarter between grant date and June 30, 2018, and an additional 3,825 RSAs that will vest during the same period if the total revenue reported in the publicly released GAAP financials exceeds $100 million."}],"balance_after":21239,"source":{"system":"sec-edgar","filing":"0001209191-16-149228","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919116149228/doc4.xml","form_type":"4"}},{"id":4592323,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Regulatory Affairs & Qual"}}],"security":"Non-Qualified Stock Options (right to buy)","published_at":"2016-10-01T01:58:17.000Z","date":"2016-09-22","kind":"exercise","acquired":false,"shares":7311,"price":13.9,"value":101622.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on March 16, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":8486,"derivative":{"exercise_price":13.9,"exercise_date":"2016-02-27","expiration_date":"2025-02-27","underlying":"Common Stock","underlying_shares":7311},"source":{"system":"sec-edgar","filing":"0001209191-16-143452","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919116143452/doc4.xml","form_type":"4"}},{"id":4592322,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Regulatory Affairs & Qual"}}],"security":"Common Stock","published_at":"2016-10-01T01:58:17.000Z","date":"2016-09-22","kind":"sale","acquired":false,"shares":7311,"price":60,"value":438660.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on March 16, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":20239,"source":{"system":"sec-edgar","filing":"0001209191-16-143452","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919116143452/doc4.xml","form_type":"4"}},{"id":4592321,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":109437,"kind":"person","name":"Ruff Shamim","position":1,"cik":"0001685986","reported_name":"Ruff Shamim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Regulatory Affairs & Qual"}}],"security":"Common Stock","published_at":"2016-10-01T01:58:17.000Z","date":"2016-09-22","kind":"exercise","acquired":true,"shares":7311,"price":13.9,"value":101622.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on March 16, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":27550,"source":{"system":"sec-edgar","filing":"0001209191-16-143452","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919116143452/doc4.xml","form_type":"4"}}]}